ADAG
Adagene Inc.
NASDAQ · Healthcare · Biotechnology · CN
$3.58
−2.98%Year over year
Reported trailing growth
- Revenue
- +1054.7%
- EBITDA
- -66.3%
- EBIT
- -75.5%
- EPS
- -71.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +186.4%
- EBITDA
- -40.5%
- EPS
- -24.0%
Three-year CAGR
- Revenue
- -6.2%
- EBITDA
- +46.8%
- EBIT
- +40.4%
- Net income
- +47.3%
- EPS
- +51.6%
- Free cash flow
- +47.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026